Document Detail

Anaplastic oligodendroglioma: advances and treatment options.
MedLine Citation:
PMID:  23344797     Owner:  NLM     Status:  PubMed-not-MEDLINE    
The optimal treatment strategy for anaplastic oligodendroglial (AO) tumors is evolving. Molecular profiling of oligodendrogliomas have shown distinctive genetic patterns characterized by combined deletions of chromosome arms 1p and 19q, O(6)-methylguanine methyltransferase (MGMT) methylation, and isocitrate dehydrogenase 1 (IDH1) mutations; they are all prognostic factors for patients with AO. In addition, a strong association has also been found between the CpG island hypermethylation phenotype (CIMP) status and MGMT promoter methylation. Long term follow up data of the Radiation Therapy Oncology Group (RTOG) 9402 and the European Organisation for Research and Treatment of Cancer (EORTC) 26951 studies demonstrate clear evidence that for patients with codeleted 1p19q AO, early chemotherapy with radiation offers a significant improvement in overall survival compared with early radiation, even with salvage chemotherapy at tumor relapse, and thus establishes the 1p19q allelic loss as a predictive marker distinct from tumors without the chromosome change. Radiotherapy alone is no longer considered an adequate treatment for this patient population. In cases with no 1p19q deletion, most neuro-oncologists recommend incorporating radiotherapy into the upfront treatment strategy. However, there are still unanswered questions regarding whether upfront chemotherapy, omitting/deferring radiotherapy, in the desire to avoid late neurocognitive toxicity of radiotherapy should be the initial therapy for AO tumors with codeleted 1p19q, or whether temozolomide, an oral agent with a better toxicity profile, can be substituted for procarbazine, lomustine, and vincristine (PCV). Further studies are warranted and the increasing understanding of molecular pathways involved may lead to more selective therapeutic targets in the future.
Mairéad G McNamara; Solmaz Sahebjam; Warren P Mason
Related Documents :
22948667 - Can we predict the prognosis of resectable hepatoblastoma from serum alpha-fetoprotein ...
23417697 - Maintenance single-agent bevacizumab or observation after first-line chemotherapy in pa...
24280437 - Can photodynamic therapy be the preferred treatment option for anal intraepithelial neo...
24611017 - Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib.
16850247 - Randomized phase ii trial of weekly paclitaxel alone versus trastuzumab plus weekly pac...
18766007 - A patient with stage iv type 4 advanced gastric cancer who had a complete pathological ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in neurology     Volume:  15     ISSN:  1092-8480     ISO Abbreviation:  Curr Treat Options Neurol     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-13     Completed Date:  2013-05-14     Revised Date:  2013-07-25    
Medline Journal Info:
Nlm Unique ID:  9815940     Medline TA:  Curr Treat Options Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  289-301     Citation Subset:  -    
Pencer Brain Tumor Centre, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Organic Anion Transporter 3 (Oat3) Interacts Selectively with Lipophilic ?-Lactam Antibiotics.
Next Document:  Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovarian surface epithe...